Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Avmapki Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy N/A

    Avmapki Fakzynja Co-Pack Coverage

    Customize your policy alerts

    Sign up for all Colorado Rocky Mountain Health Plans policy alerts

    Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and notification coverage for Avmapki Fakzynja Co-Pack (avutometinib; defactinib) for members seeking treatment for recurrent low-grade serous ovarian cancer, including automatic processing for members younger than 19 years.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyAvmapki Fakzynja Co-Pack Coverage
    Policy CodePolicy N/A
    Change TypeAnnual reviewno clinical or coverage changes
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Avmapki Fakzynja Co-Pack unless the member is younger than 19 years, when the prescription processes automatically without coverage review.
    SourceLink
    POLICY UPDATE CHANGES

    The policy underwent an annual review with no clinical or coverage changes, and the reference date was updated.

    12 moAuthorization period under age 19
    12 moInitial authorization period
    12 moReauthorization period
    3Initial therapy criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Under 19Automatic processing

    Coverage Criteria

    Patients Less Than 19 Years of Age

    Covered when the patient is less than 19 years of age.

    Patient is less than 19 years of age

    Authorization will be issued for 12 months.

    Initial Authorization

    Avmapki Fakzynja Co-Pack will be approved when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of recurrent low-grade serous ovarian cancer (LGSOC)
    • Tumor is KRAS-mutated
    • Patient has received prior systemic therapy

    Reauthorization Criteria

    Avmapki Fakzynja Co-Pack will be approved for continued coverage when the following criterion is met:

    Patient does not show evidence of progressive disease while on Avmapki Fakzynja Co-Pack therapy

    Authorization will be issued for 12 months.

    NCCN Recommended Regimens

    Coverage is available when the following criterion is met:

    The drug has been recognized for treatment of the cancer indication by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B

    Authorization will be issued for 12 months. State mandates may apply. Any federal regulatory requirements and the member-specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

    Authorization and Denial Conditions

    Prior Authorization

    Prior Authorization and Automatic Processing

    Prior authorization is required for Avmapki Fakzynja Co-Pack coverage. For members younger than 19 years, the prescription will automatically process without a coverage review; authorization is issued for 12 months when applicable.

    • Members under age 19: automatic processing without coverage review.
    • Authorization duration: 12 months.
    Denial Risk

    Initial Criteria Not Met

    Initial coverage should be denied when the member does not meet all required criteria for Avmapki Fakzynja Co-Pack.

    • Diagnosis of recurrent low-grade serous ovarian cancer (LGSOC).
    • Tumor is KRAS-mutated.

    Policy Background

    Avmapki Fakzynja Co-Pack combines avutometinib and defactinib, which are kinase inhibitors. The policy covers treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. This indication received accelerated approval based on tumor response rate and duration of response; continued approval may depend on verification and description of clinical benefit in a confirmatory trial.

    Definitions

    Definitions
    TermRecurrent low-grade serous ovarian cancer (LGSOC)
    DefinitionA low-grade serous ovarian cancer that has returned after prior treatment.
    Policy indicationAdult patients with KRAS-mutated recurrent LGSOC who have received prior systemic therapy.
    Definitions
    TermAccelerated approval
    Basis for approvalRegulatory approval based on surrogate measures, including tumor response rate and duration of response.
    Continued approval

    Initial Therapy Criteria

    Initial Authorization

    Initial therapy is covered when ALL of the following criteria are met:

    Initial ovarian cancer authorization

    • Diagnosis of recurrent low-grade serous ovarian cancer (LGSOC)
    • KRAS mutation: Tumor is KRAS-mutatedKRAS-mutated
    • Prior systemic therapy: Patient has received prior systemic therapyPrior systemic therapy required

    Patients Less Than 19 Years of Age

    Continuation and Reauthorization

    Reauthorization

    Reauthorization is covered when the following criterion is met:

    Continuation therapy: Patient does not show evidence of progressive disease while on Avmapki Fakzynja Co-Pack therapyNo progressive disease

    Authorization will be issued for 12 months.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyAvmapki Fakzynja Co-Pack Coverage
    Policy CodePolicy N/A
    Change TypeAnnual reviewno clinical or coverage changes
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Avmapki Fakzynja Co-Pack unless the member is younger than 19 years, when the prescription processes automatically without coverage review.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Denial ConditionsPolicy BackgroundDefinitionsInitial Therapy CriteriaContinuation and Reauthorization
  1. Patient has received prior systemic therapy.
  2. Denial Risk

    Progressive Disease During Therapy

    Reauthorization should be denied if the patient shows evidence of progressive disease while receiving Avmapki Fakzynja Co-Pack therapy.

    • Reauthorization requires no evidence of progressive disease during therapy.
    • Authorization duration: 12 months.
    May be contingent upon verification and description of clinical benefit in a confirmatory trial.

    Members younger than 19 years are approved when the following criterion is met:

    Pediatric age criterion: Patient is less than 19 years of age<19 years

    Prescription automatically processes without a coverage review; authorization will be issued for 12 months.

    NCCN Recommended Regimen

    Coverage may be authorized under the NCCN recommended regimen provision when the following criterion is met:

    NCCN recognition: The drug has been recognized for treatment of the cancer indication by the National Comprehensive Cancer Network (NCCN) Drugs and Biologics CompendiumNCCN Category of Evidence and Consensus 1, 2A, or 2B

    Authorization will be issued for 12 months.